Deciphera Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q1 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Deciphera Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q1 2024.
  • Deciphera Pharmaceuticals, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 30.9 %, a 13.3% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 30.9 +3.63 +13.3% Mar 31, 2024
Q4 2023 28.7 -2.2 -7.12% Dec 31, 2023
Q3 2023 28.2 -4.45 -13.6% Sep 30, 2023
Q2 2023 27.5 -5.1 -15.7% Jun 30, 2023
Q1 2023 27.3 -3.77 -12.1% Mar 31, 2023
Q4 2022 30.9 +5.61 +22.2% Dec 31, 2022
Q3 2022 32.7 +12 +57.9% Sep 30, 2022
Q2 2022 32.6 +14.4 +78.9% Jun 30, 2022
Q1 2022 31 +15.5 +99.3% Mar 31, 2022
Q4 2021 25.3 +12.2 +92.3% Dec 31, 2021
Q3 2021 20.7 +8.5 +69.6% Sep 30, 2021
Q2 2021 18.2 +8.09 +80% Jun 30, 2021
Q1 2021 15.6 +4.94 +46.4% Mar 31, 2021
Q4 2020 13.2 +1.6 +13.8% Dec 31, 2020
Q3 2020 12.2 +1.34 +12.3% Sep 30, 2020
Q2 2020 10.1 -3.09 -23.4% Jun 30, 2020
Q1 2020 10.6 -1.33 -11.1% Mar 31, 2020
Q4 2019 11.6 -0.11 -0.94% Dec 31, 2019
Q3 2019 10.9 +0.11 +1.02% Sep 30, 2019
Q2 2019 13.2 Jun 30, 2019
Q1 2019 12 Mar 31, 2019
Q4 2018 11.7 Dec 31, 2018
Q3 2018 10.8 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.